Skip to content

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery

A PhaseⅡ, Randomized, Double-Blind, Placebo- and Active- Controlled Study of YZJ-4729 Tartrate Injection for the Treatment of Moderate to Severe Pain After Orthopedic Surgery

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06901830
Enrollment
150
Registered
2025-03-30
Start date
2025-05-23
Completion date
2025-12-18
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The primary objective is to evaluate the analgesic efficacy and safety of IV YZJ-4729 Tartrate Injection in patients with acute postoperative pain following Orthopedic surgery

Interventions

Loading dose + demand dose

Loading dose + demand dose

Loading dose + demand dose

Sponsors

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent 2. BMI≥18.0 kg/m2 and ≤28.0 kg/m2 3. ASA I to II 4. Experiences a pain intensity rating of moderate to severe acute pain following orthopedic surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery

Exclusion criteria

1. Opioid allergy 2. Nervous system diseases (e.g. epilepsy) 3. Psychiatric disorders (e.g. depression) 4. History of difficult airways 5. Random blood glucose ≥11.1 mmol/L 6. Subjects with systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg or systolic blood pressure \< 90 mmHg 7. Abnormal pulse oxygen saturation (SpO2 \<92 %) 8. Abnormal liver function or renal function 9. Used agents that could affect the analgesic response 10. Used agents that could affect drug metabolism 11. Has previously participated in another YZJ-4729 clinical study

Design outcomes

Primary

MeasureTime frameDescription
The sum of pain intensity differences in pain score over 48 hours at rest48 hoursPain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NRS), with higher numbers indicating a higher pain intensity, administered over 48 hours.

Secondary

MeasureTime frameDescription
The time of first using of rescue analgesics0-48 hours
The proportion of subjects using rescue analgesics0-48 hours
The number of times for rescue analgesics using0-48 hours
The cumulative dose used of rescue analgesics0-48 hours
The resting Sum of Pain Intensity Differences Over 12,24,24~480-48 hours
The active Sum of Pain Intensity Differences Over 12,24,48,24~480-48 hours
Participant satisfaction scores for analgesia treatment48 hoursParticipants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 1 to 5, with 1 representing dissatisfied and 5 representing very satisfied
Investigator satisfaction scores for analgesia treatment48 hoursPostoperative analgesia was evaluated by investigators. The scale ranges from 1 to 5, with 1 being dissatisfied and 5 being very satisfied

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026